Efficacy of tetravalent avian IgY in treating refractory h. pylori infection

Tetravalent avian IgY offers a safe, effective alternative for managing refractory H. pylori infections, improving treatment options and reducing antibiotic reliance.

Refractory Helicobacter pylori infections complicate drug selection and treatment. This study explored the effectiveness of a novel tetravalent avian polyclonal IgY in managing such challenging cases. 

The participants were allocated randomly to receive either traditional quadruple treatment (consisting of Amoxicillin, Clarithromycin, Omeprazole, and Bismuth) for a duration of 2 weeks or tetravalent avian IgY, to be taken orally at a dosage of 250 mg twice daily for 4 weeks. The capability of IgY to bind to H. pylori antigens was evaluated using western blotting.The C-urea breath test evaluated treatment efficacy. Clinical symptoms and adverse reactions were monitored through questionnaires and routine tests. 

The binding of tetravalent IgY to VacA, HpaA, CagA, and UreB of H. pylori was confirmed by Western blot analysis. IgY showed a 50.74% eradication rate and a 50.04% inhibition rate against DOB of 13C-urea. Symptom relief was reported by 61.76% of the patients. No adverse reactions were noted during treatment.  

Tetravalent avian IgY is effective and safe for treating refractory H. pylori infections, offering a viable alternative therapeutic option with good efficacy and no reported side effects.